New antibody shot could block HIV – first human safety test underway
NCT ID NCT06585891
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of a new antibody called CAP256J3LS in 24 healthy adults aged 18 to 60. The antibody is designed to target and neutralize HIV. Participants receive either one or three doses, given as a shot under the skin or through an IV. The study monitors side effects and how long the antibody stays in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAP256J3LS (a bispecific antibody that targets HIV)
What this could lead to
If successful, this could pave the way for a new HIV prevention or treatment approach using antibodies instead of daily pills.
What could go wrong
This is an early Phase 1 safety trial with only 24 healthy participants, so it is too soon to know if the antibody will effectively prevent or treat HIV in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States